- March 4, 2020Burlingame, Calif., March 4, 2020 — Novel Machine Learning Host-Response-Based Approach Forms the Basis of Company’s Tests. Inflammatix, a pioneering molecular diagnostics company…
- January 10, 2020Burlingame, Calif., January 10, 2020 — Financing will be used to advance HostDx™ tests for acute infections and sepsis to commercial launch…
- November 14, 2019Burlingame, Calif., November 14, 2019 — HostDx Fever Test Reads the Immune System to Rapidly Diagnose Acute Infections at Point of Care. Inflammatix,…
- August 6, 2019Burlingame, Calif., August 6, 2019 — Inflammatix, a molecular diagnostics company that is reimagining diagnostics, announced today that it has received the…
- May 16, 2019Burlingame, Calif., May 16, 2019 — Inflammatix announced today that it has been named a finalist for the American Association for Clinical Chemistry’s (AACC)…
- October 4, 2018Burlingame, Calif., October 4, 2018 — Inflammatix today announced that it will present findings from two studies demonstrating the ability of its HostDx™…
- April 10, 2018Burlingame, Calif., April 10, 2018 — Inflammatix announced today that it has been named a finalist in Fast Company’s 2018 World Changing Ideas Awards for its…
- February 15, 2018Bioinformatics Approach Forms the Basis of Inflammatix’s HostDx™ Sepsis Test Burlingame, Calif., February 15, 2018 — Inflammatix announced findings from a…
- December 19, 2017BURLINGAME, Calif., Dec. 19, 2017 /PRNewswire/ — Inflammatix, a molecular diagnostics company that is developing rapid tests that read the immune system to…